Human Genome's hepatitis C drug meets main goal

[Bill1954]

” March 9 (Reuters) - Human Genome Sciences…said a its drug to treat chronic hepatitis C, albuferon, met the main goal in a second late-stage trial and expects to file for marketing approvals globally in the fall of 2009.”

http://www.reuters.com/article/rbssHealthcareNews/idUSBNG43626320090309

[Bill1954]

I agree; you’d think the convenience and other benefits such as patient compliance might trump superior efficacy, huh? Although other drugs like BOC and TPV are in the works, IFN is still the working platform involved; I think even incremental advances in interferon should be applauded. It’ll be interesting to see if this leads anywhere.

Take care—

Bill

[portann]

I guess the 'analysts' say that meeting the main goal of non-inferiority compared to Pegasys is not enough. They don't put any weight on the advantage of injecting bi-weekly, which I do.

These analysts say albuferon must show numerically BETTER SVR rates to be commercially viable. If I had a choice between weekly or bi-weekly injections, everything else being equal, I'd choose albuferon over pegasys.

Port